Voyager Therapeutics rises after Leerink starts coverage with 'outperform'

Voyager Therapeutics

16/10/2024 15:50

** Shares of Voyager Therapeutics  VYGR.O , which develops
gene therapy for rare neurological disorders, up 10.5% at $8
    ** Brokerage Leerink Partners starts coverage of VYGR with
"outperform" rating and PT of $15
    ** Brokerage says Voyager's gene therapy delivery vehicle,
known as TRACER, has unique mechanism which makes it stand out
from other platforms
    ** Leerink says VYGR's platform, which is under development
for the treatment of rare neurological diseases, has shown
improved brain penetration in various animal studies and has
high likelihood to be tested in human trials
    ** Brokerage says cash flow from company's licensing deal
for its gene therapy vehicle is significantly underappreciated
    ** Leerink also sees potential success and more
collaborations for company's Alzheimer's disease clinical
programs
    ** 9 of 10 brokerages rate stock "buy" or higher, 1 "hold";
median PT $18 - LSEG
    ** Including session moves, stock down 10% YTD

 (Reporting by Sruthi Narasimha Chari and Bhanvi Satija in
Bengaluru)
 ((sruthinarasimha.chari@thomsonreuters.com))